Report Detail
Global Dibigatran Market Insights, Forecast to 2025
- RnM3167709 |
- 22 March, 2019 |
- Global |
- 118 Pages |
- QYResearch |
- Pharma & Healthcare
The global Dibigatran market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Dibigatran market based on company, product type, end user and key regions.
This report studies the global market size of Dibigatran in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Dibigatran in these regions.
This research report categorizes the global Dibigatran market by top players/brands, region, type and end user. This report also studies the global Dibigatran market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.
The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Pfizer, Inc. (US)
Bayer Healthcare AG (Germany)
GlaxoSmithKline Plc. (UK)
Boehringer Ingelheim (Germany)
Sanofi S.A. (France)
Abbott India Limited (India)
Aspen Holdings (South Africa)
Bristol-Myers Squibb Company (US)
Eisai Inc. (US)
Mitsubishi Tanabe Pharma Corporation (Japan)
Teva Pharmaceutical Industries Ltd. (Israel)
Market size by Product
Pradaxa
Pradax
Prazaxa
Market size by End User
stroke
deep vein thrombosis
pulmonary embolism
systemic embolism
Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa
The study objectives of this report are:
To study and analyze the global Dibigatran market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Dibigatran market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Dibigatran companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Dibigatran submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
In this study, the years considered to estimate the market size of Dibigatran are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
This report includes the estimation of market size for value (million US$) and volume (Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Dibigatran market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Study Coverage
- 1.1 Dibigatran Product
- 1.2 Market Segments
- 1.3 Key Manufacturers Covered
- 1.4 Market by Type
- 1.4.1 Global Dibigatran Market Size Growth Rate by Product
- 1.4.2 Pradaxa
- 1.4.3 Pradax
- 1.4.4 Prazaxa
- 1.5 Market by End User
- 1.5.1 Global Dibigatran Market Size Growth Rate by End User
- 1.5.2 stroke
- 1.5.3 deep vein thrombosis
- 1.5.4 pulmonary embolism
- 1.5.5 systemic embolism
- 1.6 Study Objectives
- 1.7 Years Considered
2 Executive Summary
- 2.1 Global Dibigatran Market Size
- 2.1.1 Global Dibigatran Revenue 2014-2025
- 2.1.2 Global Dibigatran Sales 2014-2025
- 2.2 Dibigatran Growth Rate by Regions
- 2.2.1 Global Dibigatran Sales by Regions
- 2.2.2 Global Dibigatran Revenue by Regions
3 Breakdown Data by Manufacturers
- 3.1 Dibigatran Sales by Manufacturers
- 3.1.1 Dibigatran Sales by Manufacturers
- 3.1.2 Dibigatran Sales Market Share by Manufacturers
- 3.1.3 Global Dibigatran Market Concentration Ratio (CR5 and HHI)
- 3.2 Dibigatran Revenue by Manufacturers
- 3.2.1 Dibigatran Revenue by Manufacturers (2014-2019)
- 3.2.2 Dibigatran Revenue Share by Manufacturers (2014-2019)
- 3.3 Dibigatran Price by Manufacturers
- 3.4 Dibigatran Manufacturing Base Distribution, Product Types
- 3.4.1 Dibigatran Manufacturers Manufacturing Base Distribution, Headquarters
- 3.4.2 Manufacturers Dibigatran Product Type
- 3.4.3 Date of International Manufacturers Enter into Dibigatran Market
- 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Product
- 4.1 Global Dibigatran Sales by Product
- 4.2 Global Dibigatran Revenue by Product
- 4.3 Dibigatran Price by Product
5 Breakdown Data by End User
- 5.1 Overview
- 5.2 Global Dibigatran Breakdown Data by End User
6 North America
- 6.1 North America Dibigatran by Countries
- 6.1.1 North America Dibigatran Sales by Countries
- 6.1.2 North America Dibigatran Revenue by Countries
- 6.1.3 United States
- 6.1.4 Canada
- 6.1.5 Mexico
- 6.2 North America Dibigatran by Product
- 6.3 North America Dibigatran by End User
7 Europe
- 7.1 Europe Dibigatran by Countries
- 7.1.1 Europe Dibigatran Sales by Countries
- 7.1.2 Europe Dibigatran Revenue by Countries
- 7.1.3 Germany
- 7.1.4 France
- 7.1.5 UK
- 7.1.6 Italy
- 7.1.7 Russia
- 7.2 Europe Dibigatran by Product
- 7.3 Europe Dibigatran by End User
8 Asia Pacific
- 8.1 Asia Pacific Dibigatran by Countries
- 8.1.1 Asia Pacific Dibigatran Sales by Countries
- 8.1.2 Asia Pacific Dibigatran Revenue by Countries
- 8.1.3 China
- 8.1.4 Japan
- 8.1.5 Korea
- 8.1.6 India
- 8.1.7 Australia
- 8.1.8 Indonesia
- 8.1.9 Malaysia
- 8.1.10 Philippines
- 8.1.11 Thailand
- 8.1.12 Vietnam
- 8.1.13 Singapore
- 8.2 Asia Pacific Dibigatran by Product
- 8.3 Asia Pacific Dibigatran by End User
9 Central & South America
- 9.1 Central & South America Dibigatran by Countries
- 9.1.1 Central & South America Dibigatran Sales by Countries
- 9.1.2 Central & South America Dibigatran Revenue by Countries
- 9.1.3 Brazil
- 9.2 Central & South America Dibigatran by Product
- 9.3 Central & South America Dibigatran by End User
10 Middle East and Africa
- 10.1 Middle East and Africa Dibigatran by Countries
- 10.1.1 Middle East and Africa Dibigatran Sales by Countries
- 10.1.2 Middle East and Africa Dibigatran Revenue by Countries
- 10.1.3 GCC Countries
- 10.1.4 Turkey
- 10.1.5 Egypt
- 10.1.6 South Africa
- 10.2 Middle East and Africa Dibigatran by Product
- 10.3 Middle East and Africa Dibigatran by End User
11 Company Profiles
- 11.1 Pfizer, Inc. (US)
- 11.1.1 Pfizer, Inc. (US) Company Details
- 11.1.2 Company Business Overview
- 11.1.3 Pfizer, Inc. (US) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.1.4 Pfizer, Inc. (US) Dibigatran Products Offered
- 11.1.5 Pfizer, Inc. (US) Recent Development
- 11.2 Bayer Healthcare AG (Germany)
- 11.2.1 Bayer Healthcare AG (Germany) Company Details
- 11.2.2 Company Business Overview
- 11.2.3 Bayer Healthcare AG (Germany) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.2.4 Bayer Healthcare AG (Germany) Dibigatran Products Offered
- 11.2.5 Bayer Healthcare AG (Germany) Recent Development
- 11.3 GlaxoSmithKline Plc. (UK)
- 11.3.1 GlaxoSmithKline Plc. (UK) Company Details
- 11.3.2 Company Business Overview
- 11.3.3 GlaxoSmithKline Plc. (UK) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.3.4 GlaxoSmithKline Plc. (UK) Dibigatran Products Offered
- 11.3.5 GlaxoSmithKline Plc. (UK) Recent Development
- 11.4 Boehringer Ingelheim (Germany)
- 11.4.1 Boehringer Ingelheim (Germany) Company Details
- 11.4.2 Company Business Overview
- 11.4.3 Boehringer Ingelheim (Germany) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.4.4 Boehringer Ingelheim (Germany) Dibigatran Products Offered
- 11.4.5 Boehringer Ingelheim (Germany) Recent Development
- 11.5 Sanofi S.A. (France)
- 11.5.1 Sanofi S.A. (France) Company Details
- 11.5.2 Company Business Overview
- 11.5.3 Sanofi S.A. (France) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.5.4 Sanofi S.A. (France) Dibigatran Products Offered
- 11.5.5 Sanofi S.A. (France) Recent Development
- 11.6 Abbott India Limited (India)
- 11.6.1 Abbott India Limited (India) Company Details
- 11.6.2 Company Business Overview
- 11.6.3 Abbott India Limited (India) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.6.4 Abbott India Limited (India) Dibigatran Products Offered
- 11.6.5 Abbott India Limited (India) Recent Development
- 11.7 Aspen Holdings (South Africa)
- 11.7.1 Aspen Holdings (South Africa) Company Details
- 11.7.2 Company Business Overview
- 11.7.3 Aspen Holdings (South Africa) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.7.4 Aspen Holdings (South Africa) Dibigatran Products Offered
- 11.7.5 Aspen Holdings (South Africa) Recent Development
- 11.8 Bristol-Myers Squibb Company (US)
- 11.8.1 Bristol-Myers Squibb Company (US) Company Details
- 11.8.2 Company Business Overview
- 11.8.3 Bristol-Myers Squibb Company (US) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.8.4 Bristol-Myers Squibb Company (US) Dibigatran Products Offered
- 11.8.5 Bristol-Myers Squibb Company (US) Recent Development
- 11.9 Eisai Inc. (US)
- 11.9.1 Eisai Inc. (US) Company Details
- 11.9.2 Company Business Overview
- 11.9.3 Eisai Inc. (US) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.9.4 Eisai Inc. (US) Dibigatran Products Offered
- 11.9.5 Eisai Inc. (US) Recent Development
- 11.10 Mitsubishi Tanabe Pharma Corporation (Japan)
- 11.10.1 Mitsubishi Tanabe Pharma Corporation (Japan) Company Details
- 11.10.2 Company Business Overview
- 11.10.3 Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Sales, Revenue and Gross Margin (2014-2019)
- 11.10.4 Mitsubishi Tanabe Pharma Corporation (Japan) Dibigatran Products Offered
- 11.10.5 Mitsubishi Tanabe Pharma Corporation (Japan) Recent Development
- 11.11 Teva Pharmaceutical Industries Ltd. (Israel)
12 Future Forecast
- 12.1 Dibigatran Market Forecast by Regions
- 12.1.1 Global Dibigatran Sales Forecast by Regions 2019-2025
- 12.1.2 Global Dibigatran Revenue Forecast by Regions 2019-2025
- 12.2 Dibigatran Market Forecast by Product
- 12.2.1 Global Dibigatran Sales Forecast by Product 2019-2025
- 12.2.2 Global Dibigatran Revenue Forecast by Product 2019-2025
- 12.3 Dibigatran Market Forecast by End User
- 12.4 North America Dibigatran Forecast
- 12.5 Europe Dibigatran Forecast
- 12.6 Asia Pacific Dibigatran Forecast
- 12.7 Central & South America Dibigatran Forecast
- 12.8 Middle East and Africa Dibigatran Forecast
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
- 13.1 Market Opportunities and Drivers
- 13.2 Market Challenges
- 13.3 Market Risks/Restraints
- 13.4 Macroscopic Indicators
14 Value Chain and Sales Channels Analysis
- 14.1 Value Chain Analysis
- 14.2 Dibigatran Customers
- 14.3 Sales Channels Analysis
- 14.3.1 Sales Channels
- 14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
- 16.1 Research Methodology
- 16.1.1 Methodology/Research Approach
- 16.1.2 Data Source
- 16.2 Author Details
Summary:
Get latest Market Research Reports on Dibigatran . Industry analysis & Market Report on Dibigatran is a syndicated market report, published as Global Dibigatran Market Insights, Forecast to 2025. It is complete Research Study and Industry Analysis of Dibigatran market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
